CapsoVision, Inc. (NASDAQ: CV) continued its impressive market performance with a 7.14% surge in after-hours trading on Wednesday, building upon its strong debut as a publicly traded company. This latest jump comes on the heels of the medical technology firm's successful initial public offering (IPO) and a notable 6.90% gain during regular trading hours.

The company's IPO, which priced shares at $5 each, aimed to raise approximately $27.5 million in gross proceeds. CapsoVision offered 5.5 million shares to the public, with trading commencing on the Nasdaq under the ticker symbol "CV". The enthusiastic market reception during regular trading hours appears to have carried over into the after-hours session, reflecting sustained investor optimism about CapsoVision's prospects in the medical technology sector.

As CapsoVision prepares for its first full day of trading on Thursday, when the IPO is expected to officially close, the strong after-hours performance suggests continued investor interest. The company has also granted its underwriters a 30-day option to purchase up to an additional 825,000 shares, which could potentially increase the total funds raised. This successful market debut and the subsequent after-hours surge may set a positive tone for CapsoVision's future in the public markets, as investors appear eager to support innovative companies in the evolving medical technology landscape.